Envestnet Asset Management Inc. decreased its holdings in Sanofi (NASDAQ:SNY - Free Report) by 0.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,065,753 shares of the company's stock after selling 24,266 shares during the period. Envestnet Asset Management Inc. owned 0.12% of Sanofi worth $147,861,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Abel Hall LLC boosted its stake in Sanofi by 1.8% in the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company's stock worth $530,000 after purchasing an additional 194 shares during the period. Providence Capital Advisors LLC boosted its position in shares of Sanofi by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company's stock valued at $2,653,000 after acquiring an additional 201 shares during the period. Keudell Morrison Wealth Management grew its stake in Sanofi by 1.7% during the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company's stock valued at $624,000 after acquiring an additional 217 shares in the last quarter. Bailard Inc. increased its holdings in Sanofi by 1.4% during the 4th quarter. Bailard Inc. now owns 16,359 shares of the company's stock worth $789,000 after acquiring an additional 220 shares during the period. Finally, Old Port Advisors lifted its stake in Sanofi by 0.6% in the 4th quarter. Old Port Advisors now owns 36,704 shares of the company's stock worth $1,770,000 after purchasing an additional 232 shares in the last quarter. Institutional investors own 14.04% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on SNY shares. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Finally, The Goldman Sachs Group assumed coverage on Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price target on the stock. Three research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $62.50.
Get Our Latest Research Report on Sanofi
Sanofi Price Performance
NASDAQ:SNY traded up $1.84 during midday trading on Friday, hitting $51.50. The company had a trading volume of 3,191,009 shares, compared to its average volume of 2,326,973. The stock's fifty day moving average price is $54.97 and its 200-day moving average price is $52.35. Sanofi has a 52-week low of $45.22 and a 52-week high of $60.12. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $130.10 billion, a PE ratio of 20.68, a P/E/G ratio of 1.01 and a beta of 0.57.
Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, research analysts expect that Sanofi will post 4.36 earnings per share for the current year.
Sanofi Profile
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Further Reading
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
